8:00 AM GMT, Dec 5, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
Tenofovir 1% vaginal gel: Interim Phase IIb data
NIH's National Institute of Allergy and Infectious Diseases (NIAID) discontinued the tenofovir 1% vaginal gel arm in the open-label, African Phase IIb VOICE (MTN-003) trial after an interim analysis conducted
Read the full 303 word article